As a parent of a child with plaque psoriasis, you may already be familiar with many of the current therapies available for the treatment of moderate-to-severe plaque psoriasis in paediatric patients. They include oral medications that are used for other inflammatory conditions and biologics that are administered via subcutaneous injection. IM011-126 is a two-part research study to evaluate the safety and effectiveness of an oral investigational treatment BMS-986165 for moderate-to-severe plaque psoriasis in adolescents ages 12 to under 18 years. It is referred to as an “investigational treatment” or “study drug” because it is not yet approved for the market. BMS-986165 is currently being tested in research studies and is not an approved medicine to treat any condition. Overall, approximately 3,881 participants, across 46 research studies, have received one dose or multiple doses of the study treatment deucravacitinib.
Your child may be eligible if he or she has moderate-to-severe plaque psoriasis and is:
-4 to under 18 years of age
-Able to swallow study medication (taken with food or water)
-Showing symptoms of plaque psoriasis for 6 months or more
-Diagnosed with moderate-to-severe plaque psoriasis
This study is currently recruiting in Qld, NSW and Vic.
To learn more about this study or to find a study site near you, visit: BMSStudyConnect.com/LivingwithPsO or request a brochure for more information from Psoriasis Australia.